CrossrefInformační karta
Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis
Future Prescriber · 2012
DOI: 10.1002/fps.100 ↗Abstrakt
Abstract Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease‐related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.
EUVIMED